Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18894094 | 0.82 | GRM2 (0.40) | GRM2HSD11B1PARP1NR1H2NR1H3 | |
| SCHEMBL2157946 | 0.78 | GRM2 (0.35) | GRM2PARP1CYP11B2 | |
| SCHEMBL3323208 | 0.76 | TLR8 (0.37) | PARP1CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL5840948 | 0.74 | GRM2 (0.44) | GRM2 | |
| SCHEMBL7811170 | 0.74 | HSD11B1 (0.38) | GRM2HSD11B1PARP1NR1H2NR1H3 | |
| SCHEMBL558759 | 0.71 | TLR8 (0.41) | GRM2CYP3A4 | |
| SCHEMBL5982871 | 0.70 | GRM2 (0.39) | GRM2NOTUM | |
| SCHEMBL27249457 | 0.69 | NR1H2 (0.44) | GRM2HSD11B1PARP1NR1H2NR1H3 | |
| SCHEMBL3278279 | 0.68 | GRM2 (0.54) | GRM2HSD11B1PARP1NOTUMCYP3A4 | |
| SCHEMBL26375284 | 0.68 | CYP1A2 (0.47) | GRM2HSD11B1NR1H2NR1H3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136310-B2 | Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors | UCB Biopharma SRL (BE) | 2021-10-05 | — | — | US | disclosed |
| US-20200283416-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | CELLTECH R&D LIMITED (GB) | 2020-09-10 | — | — | US | disclosed |
| US-10464932-B2 | Iminothiadiazinane dioxide derivatives as plasmepsin V inhibitors | UCB BIOPHARMA SPRL (BE) | 2019-11-05 | — | — | US | disclosed |
| US-20190040053-A1 | Iminothiadiazinane Dioxide Derivatives as Plasmepsin V Inhibitors | UCB BIOPHARMA SPRL (BE) | 2019-02-07 | — | — | US | disclosed |
| EP-3419975-A1 | IMINOTHIADIAZINANE DIOXIDE DERIVATIVES AS PLASMEPSIN V INHIBITORS | UCB Biopharma SPRL (BE) | 2019-01-02 | — | — | EP | disclosed |
| EP-3380464-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | UCB Biopharma SPRL (BE) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017144517-A1 | IMINOTHIADIAZINANE DIOXIDE DERIVATIVES AS PLASMEPSIN V INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017089453-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2017-06-01 | — | — | WO | disclosed |
| EP-0745600-B1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-5886014-A | TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1999-03-23 | — | — | US | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283416-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | PEPD, ADAM17, ANPEP | GRM2 3288/4885HSD11B1 3255/4885PARP1 680/4885 |
| US-10464932-B2 | Iminothiadiazinane dioxide derivatives as plasmepsin V inhibitors | PEPD, CTSL, SERPINE1 | GRM2 3772/4885HSD11B1 2241/4885PARP1 1726/4885 |
| US-11136310-B2 | Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors | PEPD, ADAM17, ANPEP | GRM2 3288/4885HSD11B1 3255/4885PARP1 680/4885 |
| US-20190040053-A1 | Iminothiadiazinane Dioxide Derivatives as Plasmepsin V Inhibitors | PEPD, CTSL, SERPINE1 | GRM2 3772/4885HSD11B1 2241/4885PARP1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.